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and the Unique Role of CMR
A Paradigm Shift From “Bright Is Dead” to “Bright Is Bad”*Chiara Bucciarelli-Ducci, MD, PHD,yz Clerio F. Azevedo, MD, PHDxk“Learning never exhausts the mind.”
—Leonardo da Vinci (1)W ith an increasingly aging population,aortic stenosis (AS) has become themost frequent valvular heart disease in
North America and Europe. It is a progressive condi-
tion characterized by a long latent asymptomatic
period, followed by a shorter symptomatic stage asso-
ciated with increased morbidity and higher mortality.
Surgical aortic valve replacement (AVR) and trans-
catheter aortic valve replacement (TAVR) are the
only effective treatments for severe AS. Currently,
the timing for AVR and TAVR is based on the severity
of AS, the presence of symptoms, and/or the presence
of left ventricular (LV) systolic dysfunction (LV ejec-
tion fraction <50%). Asymptomatic patients tend to
be treated conservatively.
Nevertheless, despite these well-established cri-
teria on the appropriateness of AVR intervention,
the management of asymptomatic patients with
preserved LV systolic function continues to be con-
troversial (2). Registry data indicate that 15% of
patients undergoing AVR are asymptomatic at
the time of surgery (3). Novel markers to improve
risk stratiﬁcation would be valuable in identi-
fying asymptomatic patients who would beneﬁt
from AVR.* Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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to this work.Over the past 2 decades, cardiovascular magnetic
resonance (CMR) has been increasingly adopted in
clinical practice in the work-up of ischemic and
nonischemic cardiomyopathies (4,5). CMR is used as
an advanced diagnostic tool to accurately assess
biventricular anatomy and function, but its unique
application is in vivo myocardial tissue character-
ization. Indeed, it has been widely demonstrated
that the late gadolinium enhancement (LGE) tech-
nique allows the accurate assessment of myocardial
replacement ﬁbrosis in both ischemic and non-
ischemic cardiomyopathies. Importantly, replace-
ment ﬁbrosis by LGE has been found to represent a
ubiquitous marker of adverse prognosis in ischemic
heart disease, nonischemic dilated cardiomyopathy,
hypertrophic cardiomyopathy, cardiac sarcoidosis,
cardiac amyloidosis, and biopsy-proven myocarditis
(6–11). This suggests that the time has come for a
paradigm shift from “bright is dead” to “bright
is bad.” Myocardial enhancement is not only a
marker of myocardial scarring/necrosis, as seen in
ischemic heart disease, as it represents a broader
spectrum of myocardial damage in a variety of
cardiomyopathies.
In the context of severe AS, the degree of
myocardial ﬁbrosis plays an important role in the
transition from well-compensated hypertrophy to
overt heart failure and risk of sudden cardiac death
(12), suggesting that LGE is a marker of more
advanced disease (13).SEE PAGE 144In this issue of the Journal, Barone-Rochette et al.
(14) report the prognostic signiﬁcance of LGE in 154
patients undergoing AVR for severe AS (aortic valve
area 0.71  0.17 cm2, mean gradient 49  17 mm Hg).
Overall, they evaluated a low-risk population with
no previous myocardial infarction, normal ejection
fraction (84% of patients), and low surgical risk
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156scores. Symptoms were relatively mild; only 20%
of patients had chest pain, 27% were in New York
Heart Association functional class III/IV, and 7% had
a history of syncope. They also excluded patients
with previous AVR or coronary artery bypass surgery
and those with coexisting severe aortic regurgita-
tion and/or other severe valve disease—all factors
that would have otherwise impacted assessment of
prognosis.
Replacement myocardial ﬁbrosis by LGE was
identiﬁed in nearly one-third of the patients (28%),
with either an ischemic (9%) or nonischemic pattern
(19%). One might speculate, as patients with previ-
ous myocardial infarctions were excluded, that
the ischemic patterns could represent either small
asymptomatic infarctions (perhaps distal emboliza-
tion, given the mean infarct size of 3.5%) or myo-
cardial damage related to subendocardial ischemia
from the increased LV pressure/wall stress of
severe AS. Notably, the presence of both ischemic
and nonischemic LGE in patients with severe AS
has also been previously reported (15,16). During a
median follow-up of 2.9 years, 21 patients died
(11 cardiovascular deaths, 55% of which were sud-
den deaths). On both univariable and multivari-
able analyses, patients with pre-operative LGE had
a 2.8-fold increase in all-cause mortality com-
pared with those with no LGE. This is the ﬁrst
study to demonstrate that the prognostic value
of LGE in patients with severe AS also applies
to those undergoing TAVR. This is particularly
relevant, because TAVR candidates represent a
much higher risk population in whom the in-
dications and the timing of intervention are still
being deﬁned.
The study nicely complements previous prog-
nostic CMR studies in patients with aortic valve
disease, but it focuses on a larger, more homoge-
nous population with severe degenerative AS un-
dergoing AVR. Azevedo et al. (15) demonstrated in a
cohort of patients (28 with AS and 24 with aortic
regurgitation) that LGE was associated with less LV
functional improvement late after AVR and higher
all-cause mortality. In that study, the mortality rate
(6.8%/year) was higher than in the current study
(4.7%/year), which may reﬂect the more heteroge-
neous population with higher baseline risk in the
earlier study. Dweck et al. (16) studied 143 patients
with moderate and severe AS and reported 8- and
6-fold higher rates of all-cause mortality in patients
with nonischemic and ischemic LGE, respectively,
compared with those without LGE. However, in
that study, only 50% of the patients underwentAVR, and the remaining 50% received medical
treatment.
The major limitation of the current study is the
small number of events, which is not surprising
considering the low-risk population. Unfortunately,
the low number of patients with LGE and the low
number of events prevent a full analysis of the asso-
ciation between different LGE patterns and patient
outcome. Considering that 55% of the cardiovascular
deaths were sudden, it is possible that myocardial
ﬁbrosis as identiﬁed by LGE creates the substrate for
ventricular arrhythmia (17).
More recently, novel technical developments in
CMR have introduced T1 mapping for assess-
ment of extracellular volume, a biomarker of reac-
tive myocardial interstitial ﬁbrosis and a promising
pre-clinical marker of disease (18). T1 mapping and
extracellular volume were not performed in the
present study. However, initial experience suggests
that native (noncontrast) T1 values are increased in
patients with severe AS and to a greater extent in
symptomatic versus asymptomatic patients (19).
Flett et al. (20) conﬁrmed that diffuse interstitial
myocardial ﬁbrosis measured with equilibrium-
contrast CMR (a technique validated histologically)
is elevated in severe AS compared with normal in-
dividuals, although there is considerable overlap
between normal control subjects and AS patients.
At 6 months after AVR, diffuse myocardial ﬁbrosis
was not reversible, and the regression of LV hyper-
trophy was the result of reduced cellular mass.
Further investigation is necessary to clarify the
role of diffuse myocardial ﬁbrosis in the natural
history of AS.
An ongoing, prospective, observational cohort
study (The Role of Myocardial Fibrosis in Patients
with Aortic Stenosis; NCT01755936), is investigating
the prognostic implications of myocardial ﬁbrosis
(by LGE and T1 mapping) in patients with mild,
moderate, and severe AS. This study is seeking to
address the potential roles of LGE and T1 mapping
as new markers for risk assessment in patients
with severe AS. Whether the results of this study
will translate into more objective risk stratiﬁcation
of asymptomatic patients with severe AS, which
could trigger earlier referrals for AVR, remains to
be seen.
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